10371 studies found for:    NCI
Show Display Options
RSS Create an RSS feed from your search for:
NCI
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
Conditions: Advanced Malignant Mesothelioma;   Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma
Interventions: Drug: belinostat;   Other: laboratory biomarker analysis
2 Completed Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: tipifarnib;   Drug: etoposide
3 Active, not recruiting Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: erlotinib hydrochloride;   Drug: tipifarnib;   Other: laboratory biomarker analysis;   Other: pharmacological study
4 Active, not recruiting Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery
Conditions: Recurrent Endometrial Carcinoma;   Recurrent Ovarian Epithelial Cancer;   Stage III Endometrial Carcinoma;   Stage III Ovarian Epithelial Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Ovarian Epithelial Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: eribulin mesylate;   Drug: gemcitabine hydrochloride
5 Completed Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Meningeal Chronic Myelogenous Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: dasatinib;   Other: pharmacological study;   Other: laboratory biomarker analysis
6 Completed
Has Results
PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Conditions: Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma
Intervention: Drug: belinostat
7 Completed
Has Results
Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer
Conditions: Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Drug: dasatinib;   Other: laboratory biomarker analysis
8 Completed 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Intervention: Drug: 4'-iodo-4'-deoxydoxorubicin
9 Completed Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sunitinib malate;   Drug: gemcitabine hydrochloride
10 Completed Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
Conditions: Recurrent Prostate Cancer;   Stage IV Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: tanespimycin;   Drug: docetaxel
11 Completed Letrozole in Treating Healthy Postmenopausal Women at High Risk for Breast Cancer
Condition: Lobular Breast Carcinoma in Situ
Interventions: Drug: letrozole;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
12 Not yet recruiting Blinatumomab in Treating Younger Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: dexamethasone;   Drug: vincristine sulfate;   Drug: pegaspargase;   Drug: mitoxantrone hydrochloride;   Drug: methotrexate;   Drug: therapeutic hydrocortisone;   Drug: cytarabine;   Drug: leucovorin calcium;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: asparaginase;   Procedure: allogeneic hematopoietic stem cell transplantation;   Biological: blinatumomab;   Drug: mercaptopurine;   Drug: thioguanine;   Other: laboratory biomarker analysis;   Other: pharmacological study
13 Active, not recruiting Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Acute Promyelocytic Leukemia (M3);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: azacitidine;   Drug: vorinostat;   Other: laboratory biomarker analysis;   Other: pharmacological study
14 Completed Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer
Conditions: Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Biological: aldesleukin;   Drug: bryostatin 1;   Other: laboratory biomarker analysis
15 Completed Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors
Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: filgrastim;   Drug: cyclophosphamide;   Drug: tirapazamine
16 Completed
Has Results
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
Conditions: Anaplastic Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma
Intervention: Drug: tanespimycin
17 Completed Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: FOLFIRI regimen;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium
18 Active, not recruiting Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cilengitide;   Other: clinical observation;   Other: laboratory biomarker analysis
19 Terminated Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: imatinib mesylate;   Drug: temsirolimus;   Other: laboratory biomarker analysis
20 Active, not recruiting
Has Results
Cediranib Maleate With or Without Dasatinib in Patients With Hormone-Resistant Prostate Cancer Resistant to Treatment With Docetaxel
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer
Interventions: Drug: cediranib maleate;   Drug: dasatinib;   Procedure: assessment of therapy complications;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years